Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RSV vaccine shows promise for seniors in china

NCT ID NCT06551181

Vaccine Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental RSV vaccine in adults aged 60 and older in China. The goal was to see if the vaccine produces a strong immune response similar to that seen in older adults from other countries, where the vaccine already proved effective. About 2,620 participants took part, and researchers also monitored safety and any RSV-related illnesses in the Chinese group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

2,620 people

The number who actually took part.

Started

Aug 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult male or female of ≥60 YOA at the time of study intervention administration, who live in the community dwelling (CD participants). * Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only), ability to access and utilize a phone or other electronic communications). * Participants who are medically stable in the opinion of the investigator at the time of vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable. * Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study specific procedure. Exclusion Criteria: Medical Conditions: * History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s). * Any clinical conditions for which serum samples would be prohibited for transfer to local central lab for testing. These clinical conditions include hepatitis B, hepatitis C, HIV and Syphilis based on medical history and physical examination (all participants) and laboratory screening tests (overseas participants). * Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., current malignancy, human immunodeficiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required). * Any history of dementia or any medical condition that moderately or severely impairs cognition. * Recurrent history or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g. completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only). * Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 1 year). * Serious or unstable chronic illness. * Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant Therapy: * Previous vaccination with RSV vaccine. * Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the dose of study intervention(s), or their planned use during the study period. * Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after study intervention administration, with the exception of COVID-19 and inactivated/subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study intervention. * Administration of long-acting immune-modifying drugs or planned administration at any time during the study period (e.g., infliximab). * Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration or planned administration during the study period. * Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the study intervention administration or planned administration during the study period. For corticosteroids, this will mean prednisone \>=20 mg/day, or equivalent. Inhaled and topical steroids are allowed. Prior/Concurrent Clinical Study Experience: • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). Other Exclusion Criteria: * History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures. * Bedridden participants. * Planned move during the study conduct that prohibits participation until study end. * Participation of any study personnel or their immediate dependents, family, or household members.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial virus infections

Contacts and locations

Locations

  • GSK Investigational Site

    Shanghai, Putuo, 200065, China

  • GSK Investigational Site

    Shanghai, Putuo, China

  • GSK Investigational Site

    Shanghai, Shanghai Municipality, China

  • GSK Investigational Site

    Shanghai, 200136, China

  • GSK Investigational Site

    Shanghai, 201620, China

  • GSK Investigational Site

    Shanghai, 201901, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Espoo, 02230, Finland

  • GSK Investigational Site

    Helsinki, 00290, Finland

  • GSK Investigational Site

    Kokkola, 67100, Finland

  • GSK Investigational Site

    Oulu, 90220, Finland

  • GSK Investigational Site

    Seinäjoki, 60100, Finland

  • GSK Investigational Site

    Tampere, 33100, Finland

  • GSK Investigational Site

    Turku, 20520, Finland

  • GSK Investigational Site

    Tokyo, 160-0017, Japan

  • GSK Investigational Site

    Elblag, 82-300, Poland

  • GSK Investigational Site

    Katowice, 40-282, Poland

  • GSK Investigational Site

    Katowice, 40-600, Poland

  • GSK Investigational Site

    Krakow, 31-501, Poland

  • GSK Investigational Site

    Lodz, 91-363, Poland

  • GSK Investigational Site

    Lublin, 20-362, Poland

  • GSK Investigational Site

    Sochaczew, 96-500, Poland

  • GSK Investigational Site

    Warsaw, 00-215, Poland

  • GSK Investigational Site

    Wroclaw, 50-088, Poland

  • GSK Investigational Site

    Guri-si, 471-701, South Korea

  • GSK Investigational Site

    Incheon, 400-711, South Korea

  • GSK Investigational Site

    Seoul, 152-703, South Korea

  • GSK Investigational Site

    Ávila, 05071, Spain

  • GSK Investigational Site

    Barcelona, 08036, Spain

  • GSK Investigational Site

    Burgos, 09006, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Salamanca, 37007, Spain

  • GSK Investigational Site

    Valladolid, 47003, Spain

  • GSK Investigational Site

    Belfast, BT7 2EB, United Kingdom

  • GSK Investigational Site

    Blackpool, FY3 7EN, United Kingdom

  • GSK Investigational Site

    Bristol, BS37 4AX, United Kingdom

  • GSK Investigational Site

    Cambridgeshire, CB7 5JD, United Kingdom

  • GSK Investigational Site

    Eynsham, OX29 4QB, United Kingdom

  • GSK Investigational Site

    Hounslow, TW3 3EL, United Kingdom

  • GSK Investigational Site

    Witney, OX28 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.